Publications by authors named "S Mar"
Background: The presented study identified the appropriate ocrelizumab dosing regimen for patients with pediatric-onset multiple sclerosis (POMS).
Methods: Patients with POMS aged 10-17 years were enrolled into cohort 1 (body weight [BW] < 40 kg, ocrelizumab 300 mg) and cohort 2 (BW ≥ 40 kg, ocrelizumab 600 mg) during a 24-week dose-exploration period (DEP), followed by an optional ocrelizumab (given every 24 weeks) extension period.
Primary Endpoints: pharmacokinetics, pharmacodynamics (CD19 B-cell count); secondary endpoint: safety; exploratory endpoints: MRI activity, protocol-defined relapses, Expanded Disability Status Scale (EDSS) score change.
Differentiation protocols used to generate stem cell-derived islet cells yield heterogenous cell populations. We generated a human embryonic stem cell line that reports insulin- and glucagon-expressing cells in vitro and in vivo without altering their differentiation or function. We showed some insulin- and glucagon-expressing bihormonal cells are cell-autonomously fated to become α-like cells.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how social determinants of health (SDOH) impact pediatric-onset multiple sclerosis (POMS), particularly in terms of adverse SDOH frequency and their effects on treatment and outcomes.
- Researchers conducted a retrospective analysis of data from the United States Network of Pediatric MS Centers, focusing on various demographic and clinical outcomes related to SDOH hardships.
- Findings indicated that 66% of participants faced social hardships, which influenced factors such as age at symptom onset, steroid treatment likelihood, study attrition risk, and overall health scores.
ADEM is an inflammatory disease, with new onset polyfocal neurologic symptoms, encephalopathy and multifocal demyelination, typically in childhood. Initial diagnosis of ADEM is challenging and up to 20 % of children with MS or NMOSD are initially diagnosed with ADEM. We describe characteristics of patients with monophasic ADEM vs.
View Article and Find Full Text PDFArticle Synopsis
- There is evidence of a prodromal phase in pediatric-onset multiple sclerosis (POMS), marked by increased health care utilization prior to the first demyelinating event (FDE).
- In a study analyzing 37 POMS cases over two years before FDE, it was found that health care interactions increased significantly in the year prior (B) compared to the year before (A), including a notable rise in neurology-related encounters.
- The most common symptoms reported were neurological, particularly headaches, along with psychiatric and various non-neurological issues, highlighting the complexity of POMS symptoms leading up to FDE.